SI-BONE, Inc.
Close on Oct 19, 2026
- Market cap
- $874.42M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Si-Bone
Surgical & Medical Instruments & Apparatus, SIC 3841
The medical device company develops procedural implants and surgical instruments for patients with compromised bone, focusing on sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. Its main offerings include the iFuse line of titanium and 3D-printed implants, such as iFuse 3D, iFuse TORQ, iFuse Bedrock Granite, and iFuse TORQ TNT, alongside human bone allograft products. The company's customer base consists of healthcare professionals, primarily orthopedic spine surgeons, neurosurgeons, orthopedic trauma surgeons, and interventional spine physicians.
The company markets its products in the United States and internationally. In the United States, its commercial organization covers 16 sales regions staffed by 89 territory sales managers, 83 clinical specialists, and 320 third-party sales agents. Internationally, it distributes through 11 direct sales representatives and 28 third-party sales agents, with commercial sales in 38 countries. Additionally, surgeons have conducted more than 140,000 procedures using its products since 2009.
Summary of the business section of Si-Bone's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SI-BONE, Inc.
- Founded
- 2008
- Headquarters
- Santa Clara, CA
- Address
- 471 El Camino Real, Suite 101 95050
- Phone
- (408) 207-0700
- Website
- si-bone.com
- Employees
- 376, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- SIBN
- Exchange
- Nasdaq
- IPO date
- Oct 18, 2018
- Shares outstanding
- 45M, Jul 29, 2026
- Public float
- $800.00M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1459839
- CUSIP
- 825704109
- ISIN
- US8257041090
- LEI
- 549300J8JGYVJJHV9C31
- EIN
- 26-2216351
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Laura Francis | Chief Executive Officer, Director | 785,391 |
| Anshul Maheshwari | Chief Op & Financial Officer | 223,284 |
| Michael A. Pisetsky | SVP, Ops & Adm/Chief Legal Ofr | 273,650 |
| Jeffrey W. Dunn | Director | 117,130 |
| Jeryl L. Hilleman | Director | 43,772 |
| Timothy E. Davis JR | Director | 76,679 |
| Thomas A. West | Director | 37,947 |
| John Gordon Freund | Director | 146,025 |
| Mika Nishimura | Director | 43,673 |
| Greg K. Hinckley | Director | 105,135 |
| Daniel W. Wolf | Director | 25,857 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Dunn | $0 | $0 | $2.53M | $66 | $123 |
| FY2025 Ms. Francis | $7.45M | $10.00M | $2.53M | $66 | $123 |
| FY2025 Ms.Francis | $7.45M | $10.00M | $2.53M | $66 | $123 |
| FY2024 Mr.Dunn | $0 | $0 | $2.52M | $47 | $114 |
| FY2024 Ms. Francis | $7.09M | $2.49M | $2.52M | $47 | $114 |
| FY2024 Ms.Francis | $7.09M | $2.49M | $2.52M | $47 | $114 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 376 employees, including sales and marketing, product development, general administrative and accounting, both domestically and internationally.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 18, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 11, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |